{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:10:06Z","timestamp":1794651006721,"version":"4.9.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.vascn.2024.107570","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T17:49:01Z","timestamp":1732124941000},"page":"107570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Predicting clinical outcomes from off-target receptor interactions using Secondary Intelligence\u2122"],"prefix":"10.1016","volume":"131","author":[{"given":"Will S.","family":"Redfern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris E.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barira","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustus","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heeseung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Khalidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Bielecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Starkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeli","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Aspbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Rosenbrier Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Henderson Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare R.","family":"Gilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2024.107570_bb0005","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/bph.14617","article-title":"Updates in the function and regulation of \u03b11-adrenoceptors","volume":"176","author":"Akinaga","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0010","first-page":"1","article-title":"Effects of a monocarboxylate transport 1 inhibitor, AZD3965, on retinal and visual function in the rat","volume":"2020","author":"Allen","year":"2020","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0015","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.tranon.2019.05.018","article-title":"Clinical implications and translation of an off-target pharmacology profiling hit: Adenosine uptake inhibition in vitro","volume":"12","author":"Amouzadeh","year":"2019","journal-title":"Translational Oncology"},{"key":"10.1016\/j.vascn.2024.107570_bb0020","author":"Anon"},{"key":"10.1016\/j.vascn.2024.107570_bb0300","author":"Anon"},{"key":"10.1016\/j.vascn.2024.107570_bb0025","author":"Anon"},{"key":"10.1016\/j.vascn.2024.107570_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2024.107570_bb0035","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1476-5381.2010.00754.x","article-title":"The selectivity of \u03b2-adrenoceptor agonists at human \u03b21-, \u03b22- and \u03b23-adrenoceptors","volume":"160","author":"Baker","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0040","doi-asserted-by":"crossref","first-page":"9091","DOI":"10.1038\/s41598-024-59551-0","article-title":"L-NAC and L-NAC methyl ester prevent and overcome physical dependence to fentanyl in male rats","volume":"14","author":"Bates","year":"2024","journal-title":"Scientific Reports"},{"key":"10.1016\/j.vascn.2024.107570_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106609","article-title":"Safety screening in early drug discovery: An optimized assay panel","volume":"99","author":"Bendels","year":"2019","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107570_bb0050","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: The use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2024.107570_bb0055","article-title":"The state of the art in secondary pharmacology and its impact on the safety of new medicines","author":"Brennan","year":"2024","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2024.107570_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2165\/00002018-199411010-00003","article-title":"Adverse effects of \u03b11-adrenergic blocking drugs","volume":"11","author":"Carruthers","year":"1994","journal-title":"Drug Safety"},{"key":"10.1016\/j.vascn.2024.107570_bb0070","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bph.14103","article-title":"Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension","volume":"175","author":"Collins","year":"2018","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0075","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/toxsci\/kfy265","article-title":"Rationalizing secondary pharmacology screening using human genetic and pharmacological evidence","volume":"167","author":"Deaton","year":"2019","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2024.107570_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107098","article-title":"Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration","volume":"111","author":"Dodson","year":"2021","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107570_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2024.107542","article-title":"Preclinical mitigation of 5-HT2B agonism-related cardiac valvulopathy revisited","volume":"128","author":"Dumotier","year":"2024","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107570_bb0090","series-title":"Handbook of experimental pharmacology 208, A.D. Fryer et al. (eds.)","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-23274-9_1","article-title":"Muscarinic receptors","author":"Eglen","year":"2012"},{"key":"10.1016\/j.vascn.2024.107570_bb0095","author":"FDA Adverse Event Reporting System (FAERS)"},{"issue":"0","key":"10.1016\/j.vascn.2024.107570_bb0100","first-page":"1","article-title":"Mining drug-target and drug-adverse drug reaction databases to identify target-adverse drug reaction relationships","volume":"2021","author":"Galletti","year":"2021","journal-title":"Database"},{"key":"10.1016\/j.vascn.2024.107570_bb0105","series-title":"Principles of drug action: The basis of pharmacology","author":"Goldstein","year":"1974"},{"key":"10.1016\/j.vascn.2024.107570_bb0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharmthera.2009.03.002","article-title":"Target site occupancy: Emerging generalizations from clinical and preclinical studies","volume":"122","author":"Grimwood","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2024.107570_bb0115","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.1038\/ncomms7715","article-title":"Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate","volume":"31","author":"Hameed","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.vascn.2024.107570_bb0120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1476-5381.2011.01415.x","article-title":"On the relationship between block of the cardiac Na+ channel and drug-induced prolongation of the QRS complex","volume":"164","author":"Harmer","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102837","article-title":"Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology","volume":"57","author":"Ietswaart","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vascn.2024.107570_bb0130","author":"IUPHAR-BPS Guide to Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/10998004211000443","article-title":"Olanzapine administration reduces chemotherapy-induced nausea behavior in rats","volume":"23","author":"Jaime-Lara","year":"2021","journal-title":"Biological Research for Nursing"},{"key":"10.1016\/j.vascn.2024.107570_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106869","article-title":"A practical guide to secondary pharmacology in drug discovery","volume":"105","author":"Jenkinson","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107570_bb0145","series-title":"A pharmacology primer","author":"Kenakin","year":"2019"},{"key":"10.1016\/j.vascn.2024.107570_bb0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.vascn.2017.02.020","article-title":"Potential functional and pathological side effects related to off-target pharmacological activity","volume":"87","author":"Lynch","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107570_bb0155","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/bph.13008","article-title":"Localization of \u03b1-adrenoceptors: JR Vane Medal Lecture","volume":"172","author":"McGrath","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0192623317690609","article-title":"Regulatory Forum Review: Utility of in vitro secondary pharmacology data to assess risk of drug-induced valvular heart disease in humans: Regulatory considerations","volume":"45","author":"Papoian","year":"2017","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.vascn.2024.107570_bb0165","doi-asserted-by":"crossref","first-page":"zsad112","DOI":"10.1093\/sleep\/zsad112","article-title":"Quiet wakefulness: The influence of intraperitoneal and intranasal oxytocin on sleep-wake behavior and neurophysiology in rats","volume":"46","author":"Raymond","year":"2023","journal-title":"Sleep"},{"key":"10.1016\/j.vascn.2024.107570_bb0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2024.107570_bb0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.vascn.2010.06.008","article-title":"Evaluation of a convenient method of assessing rodent visual function in safety pharmacology studies: Effects of sodium iodate on visual acuity and retinal morphology in albino and pigmented rats and mice","volume":"63","author":"Redfern","year":"2011","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107570_bb0180","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1476-5381.1995.tb16415.x","article-title":"A re-evaluation of the role of \u03b12-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat","volume":"116","author":"Redfern","year":"1995","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.taap.2016.12.021","article-title":"A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm","volume":"317","author":"Rosenbrier Ribeiro","year":"2017","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fnbeh.2020.00058","article-title":"Altered sexual behavior in dopamine transporter (DAT) knockout male rats: A behavioral, neurochemical and intracerebral microdialysis study","volume":"14","author":"Sanna","year":"2020","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.vascn.2024.107570_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2022.107205","article-title":"Analysis of secondary pharmacology assays received by the US Food and Drug Administration","volume":"117","author":"Scott","year":"2022","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107570_bb0200","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/acs.chemrestox.0c00294","article-title":"Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and post-marketing reports","volume":"34","author":"Smit","year":"2021","journal-title":"Chemical Research in Toxicology"},{"key":"10.1016\/j.vascn.2024.107570_bb0205","series-title":"Behavioural neuroscience: A practical approach","first-page":"107","article-title":"The watermaze","volume":"Vol I","author":"Stewart","year":"1992"},{"key":"10.1016\/j.vascn.2024.107570_bb0210","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1038\/s41467-023-40064-9","article-title":"A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs","volume":"14","author":"Sutherland","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.vascn.2024.107570_bb0215","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/FBP.0b013e328363d1e2","article-title":"A proactive nonclinical drug abuse and dependence liability assessment strategy: A sponsor perspective","volume":"24","author":"Swedberg","year":"2013","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.vascn.2024.107570_bb0220","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","volume":"109","author":"Vargas","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2024.107570_bb0225","first-page":"116","article-title":"Towards a drug concentration effect relationship for QT prolongation and torsades de pointes","volume":"5","author":"Webster","year":"2002","journal-title":"Current Opinion in Drug Discovery & Development"},{"key":"10.1016\/j.vascn.2024.107570_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12358","article-title":"Reduced exercise capacity occurs before intrinsic skeletal muscle dysfunction in experimental rat models of pulmonary hypertension","volume":"14","author":"Zhang","year":"2024","journal-title":"Pulmonary Circulation"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871924000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871924000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T08:28:07Z","timestamp":1738657687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871924000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":46,"alternative-id":["S1056871924000807"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107570","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting clinical outcomes from off-target receptor interactions using Secondary Intelligence\u2122","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107570"}}